TABLE 2.
Associations between methylation levels of 18 CpGs on ChrY and age among study participants
| CpG | Position | Mapped Gene | Relation to Gene | Discovery stage | Validation stage | Meta‐analysis of both stages | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β | SE | p | β | SE | p | β | SE | p | FDR | ||||
| cg01707559 | 6778695 | TBL1Y | TSS200 | 3.51 | 0.66 | 1.95E−07 | 0.67 | 0.27 | 1.38E−02 | 1.08 | 0.25 | 1.80E−05 | 3.24E−05 |
| cg03441493 | 14074417 | 2.08 | 0.56 | 2.63E−04 | 0.55 | 0.27 | 3.82E−02 | 0.83 | 0.24 | 5.74E−04 | 6.88E−04 | ||
| cg09093035 | 14074689 | 3.09 | 0.55 | 4.18E−08 | 0.94 | 0.26 | 3.80E−04 | 1.34 | 0.24 | 1.97E−08 | 1.18E−07 | ||
| cg03258315 | 14077975 | 2.31 | 0.69 | 9.58E−04 | 0.62 | 0.27 | 2.03E−02 | 0.84 | 0.25 | 7.88E−04 | 8.34E−04 | ||
| cg09730640 | 14533708 | 3.36 | 0.56 | 3.33E−09 | 0.86 | 0.28 | 2.63E−03 | 1.38 | 0.25 | 5.06E−08 | 1.82E−07 | ||
| cg25032547 | 14773536 | TTTY15 | TSS1500 | 2.14 | 0.58 | 2.23E−04 | 0.55 | 0.27 | 4.61E−02 | 0.84 | 0.25 | 6.34E−04 | 7.13E−04 |
| cg17816615 | 15019332 | DDX3Y | Body | −2.09 | 0.59 | 4.09E−04 | −0.95 | 0.28 | 6.05E−04 | −1.16 | 0.25 | 3.53E−06 | 7.06E−06 |
| cg26198148 | 15814685 | TMSB4Y | TSS1500 | 2.28 | 0.61 | 2.02E−04 | 0.95 | 0.28 | 6.20E−04 | 1.18 | 0.25 | 2.96E−06 | 6.66E−06 |
| cg04691144 | 16634373 | NLGN4Y | TSS1500 | 4.62 | 0.65 | 6.74E−12 | 0.70 | 0.30 | 1.75E−02 | 1.36 | 0.27 | 4.00E−07 | 1.20E−06 |
| cg27443332 | 16634795 | NLGN4Y | Body | 2.52 | 0.57 | 1.03E−05 | 1.11 | 0.28 | 1.05E−04 | 1.40 | 0.25 | 4.08E−08 | 1.82E−07 |
| cg03706273 | 16635745 | NLGN4Y | 1stExon | 3.41 | 0.67 | 5.82E−07 | 0.61 | 0.29 | 3.36E−02 | 1.04 | 0.26 | 7.76E−05 | 1.16E−04 |
| cg03244189 | 21238472 | TTTY14 | Body | 2.06 | 0.63 | 1.11E−03 | 0.67 | 0.28 | 1.79E−02 | 0.90 | 0.26 | 4.43E−04 | 5.69E−04 |
| cg13845521 | 21238886 | TTTY14 | Body | 2.89 | 0.55 | 3.03E−07 | 0.78 | 0.28 | 6.09E−03 | 1.22 | 0.25 | 1.43E−06 | 3.68E−06 |
| cg11816202 | 21239332 | TTTY14 | TSS200 | 2.56 | 0.57 | 8.43E−06 | 0.68 | 0.28 | 1.70E−02 | 1.05 | 0.25 | 3.16E−05 | 5.17E−05 |
| cg15345074 | 21239461 | TTTY14 | TSS200 | 1.67 | 0.58 | 4.37E−03 | 0.59 | 0.27 | 3.12E−02 | 0.78 | 0.25 | 1.53E−03 | 1.53E−03 |
| cg01988452 | 22736528 | EIF1AY | TSS1500 | −2.68 | 0.55 | 1.71E−06 | −1.36 | 0.26 | 3.72E−07 | −1.61 | 0.24 | 1.67E−11 | 1.50E−10 |
| cg13308744 | 22736584 | EIF1AY | TSS1500 | −4.20 | 0.53 | 1.48E−14 | −0.97 | 0.27 | 3.25E−04 | −1.64 | 0.24 | 7.71E−12 | 1.39E−10 |
| cg14467015 | 23757241 | TTTY13 | TSS1500 | −2.07 | 0.63 | 1.11E−03 | −0.72 | 0.26 | 6.88E−03 | −0.92 | 0.24 | 1.53E−04 | 2.12E−04 |
Association analyses were performed by using linear regression models in each stage, with inverse normal transformed DNA methylation β value as the independent variable, age as the dependent variable, with adjustment for BMI, smoking status, drinking status, white blood cell counts and experimental batch (only in the discovery stage). Results from discovery and validation stages were combined by using a fixed‐effect meta‐analysis.